Peptide fact-sheet · English

BPC-157

Synthetic pentadecapeptide (gastric juice-derived, Body Protection Compound)

Pentadecapeptide derived from human gastric juice; preclinical evidence only, no regulatory approval, WADA-prohibited.

Translated and adapted from the canonical Portuguese version: /peptideos/bpc-157.

Quick answer

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a protein identified in human gastric juice. The original characterization and the bulk of the published evidence base come from Predrag Sikiric and colleagues at the University of Zagreb beginning in the early 1990s. The molecule is studied in preclinical models — primarily rats — for tendon and ligament repair, gastrointestinal mucosal protection, vascular and endothelial effects, and central nervous system signaling. As of May 2026, BPC-157 has no FDA, EMA, or other regulatory approval as a finished drug product, and no completed phase 3 human trial exists in peer-reviewed indexed literature. The WADA 2026 Prohibited List classifies BPC-157 under category S0 (non-approved substances) at all times, in and out of competition. The FDA placed BPC-157 in Category 2 of the 503A bulk substances list in 2023, restricting compounding access; an HHS announcement in February 2026 signaled a planned reclassification to Category 1 with physician prescription, but the formal FDA listing and state-level implementation were still pending as of May 2026. Marketing and direct-to-consumer sale of BPC-157 in the United States, the United Kingdom, the European Union, and most national jurisdictions is not authorized.

What it is

BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. It is a fragment of a protein characterized in human gastric juice and was first isolated and described by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The original publications established the pentadecapeptide as the active component of a larger gastric-juice-derived compound the group designated "Body Protection Compound" (BPC), with the fragment numbered 157.

The molecule does not have an INN, is not listed in any national pharmacopoeia, and has never completed a phase 3 randomized clinical trial in humans. The published literature in PubMed-indexed journals is dominated by preclinical work — predominantly rat and mouse models, with a smaller body of in vitro studies — and a limited number of small human pharmacokinetic or tolerability evaluations.

Material labeled "BPC-157" is widely available through "research peptide" suppliers and compounding pharmacies in some jurisdictions. The 2023 FDA placement of BPC-157 in Category 2 of the 503A bulk substances list reflected the agency's assessment that available safety data did not support compounding from bulk substance under section 503A of the Federal Food, Drug, and Cosmetic Act. The February 2026 HHS announcement signaled a planned reclassification to Category 1, which would restore compounding pharmacy access with a physician prescription, but the formal FDA listing and state-level implementation remained pending as of May 2026.

Mechanism of action

The mechanistic literature on BPC-157 is preclinical. The most consistently described pathways in animal and in vitro studies are:

Angiogenesis — upregulation of VEGFR2 signaling and endothelial nitric oxide synthase (eNOS) activity, with downstream nitric oxide-mediated effects on capillary formation.
Fibroblast activity and extracellular matrix — stimulation of fibroblast migration and collagen deposition in tendon and ligament injury models.
Anti-inflammatory effects — modulation of pro-inflammatory cytokines in gastrointestinal injury models.
Gastrointestinal mucosal protection — effects on ulcer healing in chemically induced rat models (one of the earliest characterized actions, traceable to the original Sikiric work in the 1990s).
Neuromuscular signaling and central nervous system effects — effects on dopaminergic and serotonergic pathways reported in rodent models, though human relevance is uncharacterized.

The proposed pathways are mechanistically plausible at the cellular level and consistent across multiple independent preclinical reports. They do not, however, substitute for randomized controlled human evidence on clinical outcomes, which remains absent in peer-reviewed indexed literature.

What the trials show

The published clinical evidence on BPC-157 in humans is sparse and, as of May 2026, does not include any peer-reviewed phase 2 or phase 3 randomized controlled trial with clinically meaningful endpoints. The literature consists of:

Preclinical studies — hundreds of indexed publications, predominantly rodent models, characterizing healing of tendon, ligament, muscle, gastrointestinal mucosa, and bone; angiogenesis; neuroprotection; and gastric ulcer models. The work of Sikiric and colleagues anchors the field. Several independent groups have contributed.
Preclinical safety — toxicology studies in rats, mice, rabbits, and dogs reporting good tolerability at the doses tested. Published preclinical safety evaluations have not identified serious toxicity at typical investigational dose ranges.
Human data — a small number of case reports and uncontrolled clinical observations in orthopedic and gastrointestinal contexts. No randomized controlled trial with placebo and clinically meaningful endpoints has been published in peer-reviewed indexed literature.

The 2025 systematic review of BPC-157 in orthopedic sports medicine (Vasireddi et al., Sports Health, 2025) and recent narrative reviews on musculoskeletal healing consistently identify the same gap: animal data are encouraging, but the human evidence required to support a clinical indication is not available. The MDPI 2025 literature and patent review reached the same conclusion.

Generalizing rodent results — particularly across different injury models, dosing regimens, and timing windows — to a human therapeutic claim is not supported by current evidence. The absence of a randomized human trial is the central editorial point.

Pharmacokinetics

Human pharmacokinetic data are not published in peer-reviewed indexed literature. Preclinical reports describe a short circulating half-life for the native pentadecapeptide in plasma (minutes) with local-tissue persistence longer than plasma exposure would predict. Routes investigated preclinically include subcutaneous, intramuscular, intraperitoneal, and oral administration. The oral route's bioavailability in humans is not characterized.

Dosing regimens used in compounding practice and research-peptide commerce vary widely and are not based on validated human pharmacokinetic data.

Safety and adverse events

The safety database on BPC-157 in humans is limited to small case series and uncontrolled clinical observations. No comprehensive pharmacovigilance dataset exists. Preclinical toxicology in rodents, rabbits, and dogs has reported tolerability at the dose ranges tested, with few serious events.

The principal safety concerns are structural to the regulatory situation:

Absence of long-term human safety data — no published cohort with multi-year follow-up.
Variable supply quality — material sold as "BPC-157" outside of a regulated pharmaceutical supply chain is not consistently characterized by HPLC, peptide mapping, or impurity profiling. Identity, purity, and endotoxin content cannot be assumed.
Concurrent use with other peptides — combination protocols common in non-medical use have not been studied for pharmacologic interactions or cumulative effects.

The absence of harm signal in small preclinical and clinical reports is not equivalent to demonstrated safety in human use over months or years. It is documented ignorance, not evidence of absence.

Regulatory status (international)

FDA: not approved as a finished drug product. Placed in Category 2 of the 503A bulk substances list in 2023, restricting compounding from bulk substance. The HHS announcement on February 27, 2026 indicated a planned reclassification of BPC-157 (and 13 other peptides) to Category 1, which would restore compounding pharmacy access with a physician prescription. As of May 2026, the formal FDA listing and state-level implementation were pending; compounding access status was therefore in transition and varied by state.
EMA: no marketing authorization. No European Medicines Agency assessment for any indication.
INN (WHO): not assigned.
WADA: prohibited at all times under category S0 (non-approved substances) in the 2026 Prohibited List. Because BPC-157 has never received regulatory approval, the therapeutic-use exemption (TUE) criteria cannot be satisfied.
United Kingdom, Australia, Canada: no marketing authorization. Treated as an unapproved substance under respective national frameworks.

Marketing of BPC-157 in dietary supplement form is not permitted in the United States; the FDA has taken enforcement action against products making therapeutic claims.

What we still don't know

Whether any of the preclinical effects characterized in rodent models translate to clinically meaningful outcomes in humans.
Human pharmacokinetics, bioavailability by different routes, and dose-response across plausible indications.
Long-term safety in human use beyond a few months.
Comparative effectiveness versus standard of care for any orthopedic, gastrointestinal, or vascular indication.
Whether the FDA's planned reclassification to 503A Category 1 will proceed and how state pharmacy boards will implement compounding access.

Why it matters

BPC-157 is the most-discussed peptide in the "research peptide" commerce and in non-medical wellness contexts in 2026, and the gap between the volume of marketing claims and the volume of peer-reviewed human evidence is unusually wide. The preclinical pathway is mechanistically plausible and supported by multiple independent groups. The leap from rodent injury models to a human therapeutic indication is not supported by published phase 2 or phase 3 randomized controlled trials. The regulatory situation — FDA Category 2 in 2023, planned move toward Category 1 in 2026 still in transition, WADA S0 prohibition, no EMA assessment, no INN — reflects this gap. Editorial coverage that conflates promising preclinical mechanism with established clinical benefit misrepresents what the literature shows. A serious clinical case for BPC-157 requires the evidence layer that does not yet exist.